Meta AnalysisID 2455
雷洛昔芬辅助治疗精神分裂症：一项随机对照试验的Meta分析
CRD42017059946
Selective estrogen receptor modulators (SERMs) such as raloxifene have already shown beneficial effects on negative, positive and general psychopathology symptoms in postmenopausal women with schizophrenia. Thus, this st
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2455
- Evidence Id
- 11013
- Core Evidence Id
- 11013
- Source Meta Analysis Id
- 2403
- Herb2 Meta Analysis Id
- HBMA002403
- Crd Id
- CRD42017059946
- Title
- Adjunctive raloxifene for schizophrenia: a meta of randomized controlled trials
- Review Question
- Selective estrogen receptor modulators (SERMs) such as raloxifene have already shown beneficial effects on negative, positive and general psychopathology symptoms in postmenopausal women with schizophrenia. Thus, this study is aimed to assess the efficacy and safety of raloxifene for schizophrenia based on randomized controlled trials (RCTs) with meta-analyzable data.
- Study Type Included
- Only randomized controlled studies were eligible.
- Condition Being Studied
- Selective estrogen receptor modulators (SERMs) as estrogen both agonists and antagonists also appeared to have an estradiol-like impact on brain neurochemistry and adjuvant therapy to antipsychotics but without peripheral adverse effects of estradiol. Raloxifene as a first generation SERM showed efficacy in improving cognition and psychopathologic symptoms in postmenopausal women.
- Participant
- Patients with schizophrenia
- Animal
- Human Disease Modelled
- Intervention
- Raloxifene plus antipsychotics (APs)
- Comparator Control
- APs plus placebo or APs monotherapy.
- Main Outcome
- The mean change in total scores on the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) or Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962).
- Outcome Measure
- Additional Outcome
- 1) the mean change in positive, negative, and general psychopathology subscales of the PANSS or the BPRS or the total scores of the Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen, 1984) and/or the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1983); 2) all cause discontinuation; 3) tolerability outcomes.
- Study Method
- Meta-analysis
- Keyword
- Antipsychotic Agents; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Schizophrenia
- Contact
- Dr Dong-Bin [email protected]
- Organisational Affiliation
- http://www.gztcm.com.cn/ http://www.gztcm.com.cn/
- Funding Source
- Other Selection Criteria
- Final Publication
- Zhu XM, Zheng W, Li XH, Cai DB, Yang XH, Ungvari GS, Ng CH, Wang XP, Kulkarni J, Grigg J, Ning YP, Xiang YT. Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Schizophr Res. 2018 Feb 5. pii: S0920-9964(18)30037-9. doi: 10.1016/j.schres.2018.01.017. [Epub ahead of print] doi:
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Completed published
- First Submission Date
- 2018-02-28
- Registration Date
- 2017-03-22
- Anticipated Start Date
- 2017-03-01
- Anticipated Completion Date
- 2018-03-01
- Title Cn
- 雷洛昔芬辅助治疗精神分裂症：一项随机对照试验的Meta分析
- Title En
- Adjunctive raloxifene for schizophrenia: a meta of randomized controlled trials
- Bilingual Status
- complete